...
首页> 外文期刊>Diabetes research and clinical practice >Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.
【24h】

Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.

机译:葡萄糖耐量受损受试者的风险评分模型的开发和验证,用于评估2型糖尿病的风险-STOP-NIDDM风险评分。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: To develop a risk-score model, based on available clinical data to assess absolute risk of type 2 diabetes among people with impaired glucose tolerance (IGT). METHODS: Data from the study to prevent non-insulin dependent diabetes mellitus (STOP-NIDDM) investigating acarbose treatment in individuals with IGT were used to develop multivariable Cox proportional hazards model for the time to onset of diabetes. The final model equation was externally validated using data from the Finnish Cardiovascular Risk Factor (FINRISK) population. RESULTS: The risk-score model included the variables acarbose treatment, gender, serum triglyceride level, waist circumference, fasting plasma glucose, height, history of cardiovascular disease (CVD) and hypertension. The final model yielded an area under the receiver-operating-characteristic curve (AUC(ROC)) of 0.64 when applied to people with IGT in the STOP-NIDDM, and 0.84 and 0.90 when applied to FINRISK population with IGT alone and IGT and normal glucose tolerance combined, respectively; AUC(ROC) is a measure of the discriminatory power of the model (1, perfect discrimination). CONCLUSIONS: The STOP-NIDDM risk-score is a simple and validated tool that can identify high-risk individuals with IGT who would benefit most from type 2 diabetes or CVD prevention strategies, such as lifestyle management or early acarbose treatment.
机译:目的:根据现有临床数据建立风险评分模型,以评估糖耐量受损(IGT)患者中2型糖尿病的绝对风险。方法:用于研究非胰岛素依赖型糖尿病(STOP-NIDDM)的研究数据(IGP患者接受阿卡波糖治疗)被用于建立糖尿病发病时间的多变量Cox比例风险模型。最终的模型方程式是使用来自芬兰心血管危险因素(FINRISK)人群的数据进行外部验证的。结果:风险评分模型包括阿卡波糖治疗,性别,血清甘油三酯水平,腰围,空腹血糖,身高,心血管病史和高血压的变量。最终模型在STOP-NIDDM中应用于IGT患者时,在接收器操作特性曲线下的面积(AUC(ROC))为0.64,而对于仅使用IGT,IGT和正常情况下的FINRISK人群,则得到0.84和0.90分别合并葡萄糖耐量; AUC(ROC)是模型歧视能力的度量(1,完全歧视)。结论:STOP-NIDDM风险评分是一种简单且经过验证的工具,可以识别患有IGT的高风险患者,这些患者将从2型糖尿病或CVD预防策略(例如生活方式管理或早期阿卡波糖治疗)中受益最多。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号